Source link : https://www.newshealth.biz/health-news/fda-expands-approval-of-il-23-drug-to-ulcerative-colitis/
The FDA expanded the indications for guselkumab (Tremfya) to include adults with moderately to severely active ulcerative colitis, Johnson & Johnson announced on Wednesday. Approval of the dual-acting interleukin (IL)-23 inhibitor in ulcerative colitis was based on findings from QUASAR, an ongoing phase IIb/III induction and maintenance program involving patients with inadequate response to conventional […]
Author : News Health
Publish date : 2024-09-12 17:28:51
Copyright for syndicated content belongs to the linked Source.
Categories